TipRanks

Notifications

KKR Snaps Up Majority Stake In Therapy Brands

Global investment firm KKR is acquiring a majority stake in Therapy Brands. The latter is a practice management and electronic health record (EHR) platform for behavioral healthcare practices.

Max Lin, KKR (KKR) partner and co-lead of KKR’s Americas Private Equity business health care industry team, said, “We are delighted to be backing Therapy Brands at a time when there is increasing recognition and social awareness about the importance of mental health.”  

Lin added, “Therapy Brands has developed an impressive portfolio of best-in-class software tools and mission-critical solutions to help mental health providers modernize their practices.” (See KKR stock analysis on TipRanks)

KKR is acquiring the majority stake from existing investors, funds associated with Lightyear Capital LLC, Oak HC/FT, and Greater Sum Ventures. Existing investor, PSG, will continue to be a minority stakeholder in Therapy Brands.

Currently, Therapy Brands serves more than 28,000 healthcare practices across the U.S. Along with practice management and EHR, it also offers telehealth, data collection, revenue cycle management, and e-prescribing services.

KKR’s other behavioral healthcare investments include Blue Sprig Pediatrics and BrightSpring Health Services. It also has invested in healthcare technology companies WebMD and Clarify Health.

Recently, Oppenheimer analyst Chris Kotowski assigned the stock a Buy rating with a $53 price target (3.8% upside potential).

Kotowski commented, “KKR has used its balance sheet to help seed and develop a real assets platform that now has $38B in commitments, up from literally zero a decade ago.” The analyst also expects KKR’s April 14 investor day to “give confidence in a strong growth trajectory.”

Consensus on the Street is that KKR is a Moderate Buy, based on 8 Buys and 3 Holds. The average analyst price target of $53.55 implies an upside potential of 4.9%. Shares have gained about 111.6% over the past year.

Related News:
Beyond Meat Opens First Manufacturing Facility In China
Nokia Settles Patent Dispute With Lenovo
Fox Files Suit Against Flutter Over Stake Dispute In Sports Betting Firm FanDuel

Tags:
Kailas Salunkhe
Kailas has been writing stock news and analysis at TipRanks since 2021, and has worked in the financial domain in various roles since 2013. Prior to joining TipRanks, he served as an equity research analyst at Globflex Research, a quant fund, and Market Realist, an equity research firm, analyzing companies listed on the stock markets in the U.S., Europe, the Middle East, and Asia. Kailas has also worked as an equity trader, covering the U.S. stock markets, for Capstone Securities, a proprietary trading firm. Kailas' key strength lies in analyzing the pharmaceutical, biotech, and mining sectors and companies falling in their ambit. A proponent of long-term investing, he is also proficient in equity research, report writing, financial modeling, and pitch decks. Kailas believes that the law of compounding can work wonders for all investors if they ace the Marshmallow test.